The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation
Open accessAbstract
Use of warfarin, clopidogrel, or aspirin associates with mortality among patients with ESRD, but the risk-benefit ratio may depend on underlying comorbidities. Here, we investigated the association between these medications and new stroke, mortality, and hospitalization in a retrospective cohort analysis of 1671 incident hemodialysis patients with preexisting atrial fibrillation. We followed patient outcomes from the time of initiation of dialysis for an average of 1.6 yr. Compared with nonuse, warfarin use associated with a significantly increased risk for new stroke (hazard ratio 1.93; 95% confidence interval 1.29 to 2.90); clopidogrel or aspirin use did not associate with increased risk for new stroke. Analysis using international normalized ratio (INR) suggested a dose-response relationship between the degree of anticoagulation and new stroke in patients on warfarin (P = 0.02 for trend). Warfarin users who received no INR monitoring in the first 90 d of dialysis had the highest risk for stroke compared with nonusers (hazard ratio 2.79; 95% confidence interval 1.65 to 4.70). Warfarin use did not associate with statistically significant increases in all-cause mortality or hospitalization. In conclusion, warfarin use among patients with both ESRD and atrial fibrillation associates with an increased risk for stroke. The risk is greatest in warfarin users who do not receive in-facility INR monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Warfarin use was associated either with a neutral or increased risk of stroke in database analyses of patients on dialysis, [419][420][421] including a population-based analysis in Canada (adjusted HR for stroke 1.14; 95% CI 0.78-1.67,adjusted HR for bleeding 1.44; 95% CI 1.13-1.85).422”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [420]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,877
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
The role of the propensity score in estimating dose-response functions
Imbens, G. W. (2000) · Biometrika · doi:10.1093/biomet/87.3.706 · Cited by 1,779
Cited by
Sorted by citations
Items 401–427 of 427
Gondolatok a direkt orális véralvadásgátló szerek használatáról krónikus vesebetegségben
Ábrahám, G. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.17
Tirmenštajn‐Janković, B. (2019) · Timocki medicinski glasnik · doi:10.5937/tmg1904170t
Therapeutic strategy of dialysis catheter‐associated massive thrombus
Imamura, T. (2020) · Journal of Cardiac Surgery · doi:10.1111/jocs.14731
A novel approach for QRS complex detection in patients with atrial arrhythmia
Giraldo-Guzmán, J., Ruiz, E., Magre, L. A., Lasprilla, G. I. B., & Kotas, M. (2020) · International Symposium on Medical Information Processing and Analysis (SIPAIM) · doi:10.1117/12.2576019
“It is estimated that AF increases the overall risk of stroke up to 5-fold [3].”
BackgroundArrhythmias in dialysis patients
Warwas, S., Jagosz, M., Średniawa, B., Mazurek, M., & Jędrzejczyk‐Patej, E. (2021) · In a good rythm · doi:10.5604/01.3001.0014.7471
Use of DOAC in Patients with Kidney Disease
Vio, R., Proietti, R., & Calò, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-74462-5_7
Yazawa, T., Yamaki, K., Kato, A., Goto, Y., Yamamoto, R., Sugiura, J., Tanaka, K., & Kato, W. (2022) · Japanese Journal of Cardiovascular Surgery · doi:10.4326/jjcvs.51.31
CHADS2 and CHA2DS2-VASc scores in evaluating the prognosis of maintenance hemodialysis patientsPreprint
Wang, L., Gong, X., Sun, G., Jiang, A., Li, B., Wang, B., Meng, J., Lu, Z. Y., Dong, H., Yu, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1375122/v1
Sherman, R. A. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00716.x
Anticoagulation Therapy in Patients with Chronic Kidney Disease
Sharif‐Askari, F. S., Sulaiman, S. A. S., & Sharif‐Askari, N. S. (2015) · Advances in experimental medicine and biology · doi:10.1007/13780_2015_4
Joki, N., 中田, 憲., & 藤﨑, 毅. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.279
Gándara-Ricardo, J. A., Sierra-Vargas, E. C., Plaza-Tenorio, M., & Rodelo-Ceballos, J. R. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.21000039
Malan, I. A. (2022) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20220171
Kim, D. G., Kim, S. H., Park, S. Y., Han, B. G., Kim, J. S., Yang, J. W., Park, Y. J., & Lee, J. Y. (2023) · medRxiv · doi:10.1101/2023.02.09.23285732
“retrospective observational studies based on large numbers of patients with ESKD showed 94 that warfarin use increased the risk of stroke and overall mortality in these patients.(8,9) 95 Therefore, the Kidney Disease: Improving Global Outcome (KDIGO) 2011 consensus 96 statement on cardiovascular disease recommended ag…”
Kobalava, Z. D. K., & Анатольевич, Ш. А. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-2-64-82
Elsayegh, M. T. (2023) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2023.318269
Vorhofflimmern und Antikoagulation bei Niereninsuffizienz
Ketteler, M. (2023) · Kardiologie up2date · doi:10.1055/a-1971-9894
López-Gutiérrez, L. V., Mora-Atehortúa, M. I., Peláez-García, S., Jaimes, F. A., Saavedra-González, Y. A., Ossa-Estrada, D. A., Villegas-Molina, J. P., Polo-Guzmán, A. H., & Saldarriaga, C. (2024) · Archivos de cardiología de México · doi:10.24875/acm.23000006
“…con CHA2DS2-VASc > 2 y ERC en hemodiálisis En un estudio observacional con 1671 pacientes con FA y ERC en hemodiálisis, publicado en el año 2009 por Chan et al. 13 , se encontró que el uso de warfarina se asoció a un riesgo significativamente mayor de AVC (HR: 1.93; IC95%: 1.29-2.90) en…”
BackgroundInfluentialLópez-Gutiérrez, L. V., Mora-Atehortúa, M. I., Peláez-García, S., Jaimes, F. A., Saavedra-González, Y. A., Ossa-Estrada, D. A., Villegas-Molina, J. P., Polo-Guzmán, A. H., & Saldarriaga, C. (2024) · Archivos de cardiolog�a de M�xico (English ed Internet) · doi:10.24875/acme.m24000482
“In an observational study with 1671 patients with AF and CKD on hemodialysis, published in 2009 by Chan et al. 13 , it was found that the use of warfarin was significantly associated with a higher risk of stroke (HR: 1.93; 95%CI, 1.29-2.90) compared to non-anticoagula-tion.”
InfluentialStroke Prevention in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review
Massé, O., Dallaire, G., Maurice, N., Hong, Y., Mercurio, C. M., Tremblay, C., Dugré, N., & Bernier-Jean, A. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290316
“%) cohort studies 29,54,55,57-59,61 ,67 ,68,70,75-77 75-77, 81,”
Outcomes Following Pulmonary Vein Isolation in ESRD Patients: USRDS-Based Outcome DataPreprint
Patel, H., Alzahrani, A., Lamont, L., Kattubadi, A., Hamon, D., Powers, E. M., Conti, S., Farjo, P. D., & Dominic, P. S. (2025) · medRxiv · doi:10.1101/2025.05.19.25327962
Bleeding in Patients with Renal Impairment: A Current Perspective
Haysom, R., Aziz, N. Z., Swan, D., & Thachil, J. V. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2731-2487
Cho, M. S., Choi, H. O., Hwang, K. W., Kim, J., Nam, G.-B., & Choi, K.-J. (2023) · Figshare · doi:10.6084/m9.figshare.22697255
Juneja, M., Khan, R., Sharma, G., Nadkarni, N. A., Gandhi, A., Rahul, C., Uddin, M. S., Sharma, S., Ambala, M., Jilakraju, B., et al. (2025) · medRxiv · doi:10.1101/2025.08.28.25334228
“However, in patients with CKD, warfarin use is complicated by a narrow therapeutic window, frequent monitoring requirements, poorer control of anticoagulation, higher risk for stroke and major hemorrhage and the potential for developing warfarin-related nephropathy [8, 9, 10].”
Soltani, A. S., Nasab, A. E., Ahangar, M. H., Khani, M. H., Bi’aragh, S. H., Rasouli, K., Afsahi, R., & Pourahmad, R. (2026) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251410932
“19 Dialysis patients also have a higher long-term incidence of GIB.”
Antithrombotic and Anticoagulant Therapy in Renal Dysfunction
Burlacu, A., & Brinza, C. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_9
Soliman, A. R., Khashab, S., Fayed, A., Abdelaziz, T. S., Momtaz, M., Zayed, B., Aly, A., & Maamoun, H. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00733-9
Metadata
- Authors
- Chan, K. E., Lazarus, J. M., Thadhani, R., & Hakim, R. M.
- Affiliations
- Fresenius Medical Care (United States) (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Chan, Kevin E.
- Lazarus, J. Michael
- Hakim, Raymond M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-10
- Volume
- 20
- Issue
- 10
- Pages
- 2223-2233
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC2754104
- OpenAlex
- W2137138584
- Cited by
- 431
- References
- 86
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 12 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 23 · 2019: 21 · 2018: 38 · 2017: 40 · 2016: 40 · 2015: 43 · 2014: 34 · 2013: 35 · 2012: 29
- FWCI
- 16.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- warfarin, stroke risk, hemodialysis, atrial fibrillation, end-stage renal disease, clopidogrel, aspirin, INR monitoring, anticoagulation, mortality, hospitalization
- MeSH terms
- Aged, Anticoagulants, Atrial Fibrillation, Female, Renal Dialysis, Hospitalization, Humans, Kidney Failure, Chronic, Male, Regression Analysis, Retrospective Studies, Risk, Warfarin, Cohort Studies, International Normalized Ratio, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
